Literature DB >> 28325263

Lipid metabolism and lung cancer.

María Merino Salvador1, Marta Gómez de Cedrón2, Juan Moreno Rubio3, Sandra Falagán Martínez4, Ruth Sánchez Martínez2, Enrique Casado4, Ana Ramírez de Molina2, María Sereno4.   

Abstract

Lung cancer is currently one of the most serious health issues in developed and developing countries. There are multiple available treatment options; however survival still remains very poor. Despite metabolism alteration being one of the hallmarks described in human cancer, lipid metabolism disorders are less known. They are recently becoming more important in this setting and therefore achieving a deeper knowledge might be helpful to obtain new strategies to accurate diagnosis, estimate prognosis, and develop therapeutic agents based on bioactive compounds such as cerulenin, SCD1, ACLY inhibitors, statins, polyphenolic compounds, etc. The present paper reviews the basis of lipid metabolism in lung cancer and suggests potential biomarkers. Further investigation is crucial to improve our knowledge in this area.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Bioactive compounds; Biomarker; Lipid metabolism; Lung cancer

Mesh:

Year:  2017        PMID: 28325263     DOI: 10.1016/j.critrevonc.2017.02.001

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN: 1040-8428            Impact factor:   6.312


  37 in total

Review 1.  Role and mechanisms of autophagy in lung metabolism and repair.

Authors:  Xue Li; Fuxiaonan Zhao; An Wang; Peiyong Cheng; Huaiyong Chen
Journal:  Cell Mol Life Sci       Date:  2021-04-17       Impact factor: 9.261

2.  GLUT5-mediated fructose utilization drives lung cancer growth by stimulating fatty acid synthesis and AMPK/mTORC1 signaling.

Authors:  Wen-Lian Chen; Xing Jin; Mingsong Wang; Dan Liu; Qin Luo; Hechuan Tian; Lili Cai; Lifei Meng; Rui Bi; Lei Wang; Xiao Xie; Guanzhen Yu; Lihui Li; Changsheng Dong; Qiliang Cai; Wei Jia; Wenyi Wei; Lijun Jia
Journal:  JCI Insight       Date:  2020-02-13

Review 3.  Long Noncoding RNAs and Circular RNAs in the Metabolic Reprogramming of Lung Cancer: Functions, Mechanisms, and Clinical Potential.

Authors:  Yuhao Zhou; Yuan Zhan; Weiling Jiang; Huiguo Liu; Shuang Wei
Journal:  Oxid Med Cell Longev       Date:  2022-06-15       Impact factor: 7.310

4.  Lung metabolome of 1,3-butadiene exposed Collaborative Cross mice reflects metabolic phenotype of human lung cancer.

Authors:  Mary Nellis; Caitlin O Caperton; Ken Liu; ViLinh Tran; Young-Mi Go; Lance M Hallberg; Bill T Ameredes; Dean P Jones; Gunnar Boysen
Journal:  Toxicology       Date:  2021-10-11       Impact factor: 4.571

5.  Induction of SREBP1 degradation coupled with suppression of SREBP1-mediated lipogenesis impacts the response of EGFR mutant NSCLC cells to osimertinib.

Authors:  Zhen Chen; Danlei Yu; Taofeek K Owonikoko; Suresh S Ramalingam; Shi-Yong Sun
Journal:  Oncogene       Date:  2021-10-11       Impact factor: 8.756

Review 6.  Biofluid lipidome: a source for potential diagnostic biomarkers.

Authors:  Arkasubhra Ghosh; Krishnatej Nishtala
Journal:  Clin Transl Med       Date:  2017-06-20

Review 7.  Lipid metabolism reprogramming and its potential targets in cancer.

Authors:  Chunming Cheng; Feng Geng; Xiang Cheng; Deliang Guo
Journal:  Cancer Commun (Lond)       Date:  2018-05-21

Review 8.  YAP and TAZ in Lung Cancer: Oncogenic Role and Clinical Targeting.

Authors:  Federica Lo Sardo; Sabrina Strano; Giovanni Blandino
Journal:  Cancers (Basel)       Date:  2018-05-06       Impact factor: 6.639

9.  Relationship of SNP rs2645429 in Farnesyl-Diphosphate Farnesyltransferase 1 Gene Promoter with Susceptibility to Lung Cancer.

Authors:  Mehdi Dehghani; Zahra Samani; Hassan Abidi; Leila Manzouri; Reza Mahmoudi; Saeed Hosseini Teshnizi; Mohsen Nikseresht
Journal:  Int J Genomics       Date:  2018-03-22       Impact factor: 2.326

10.  Heterogeneity of lipidomic profiles among lung cancer subtypes of patients.

Authors:  Jiapei Lv; Danyan Gao; Yong Zhang; Duojiao Wu; Lihua Shen; Xiangdong Wang
Journal:  J Cell Mol Med       Date:  2018-07-12       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.